Pricing and Reimbursement Application Tracker
Login
Search
pembrolizumab (Keytruda®)
Application Details
HSE Application ID
HSE100108
HTA Number
26026
HTA Link
https://www.ncpe.ie/pembrolizumab-keytruda-hta-id-26026/
Drug
pembrolizumab
Brand
Keytruda®
Applicant
Merck Sharp & Dohme B.V.
Indication Applied For
Pembrolizumab in combination with paclitaxel, with or without bevacizumab, indicated for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1 and who have received one or two prior systemic treatment regimens.
Application Date
26/05/2026
Marketing Authorisation Date
30/03/2026
Application Status
Full Health Technology Assessment Commissioned by HSE
22/06/2026
Rapid Review Completed
19/06/2026
Pricing and Reimbursement Application Complete
26/05/2026
Rapid Review Commissioned
21/05/2026
New Search
Status
Pricing and Reimbursement Application Complete
Rapid Review Commissioned
Rapid Review Completed
Applicant Meeting Held with CPU
Awaiting Proposal from Applicant
Proposal from Applicant Under Review
Full Health Technology Assessment Commissioned by HSE
NCPE Assessment Completed
HSE Drugs Group Review Pending
Reviewed by HSE Drugs Group
HSE Rare Disease Technology Review Committee - Review Requested
HSE Rare Disease Technology Review Committee - Review Received
Further Information Requested by HSE Drugs Group
Reviewed by HSE Senior Leadership Team
Managed Access Protocol (MAP) Commissioned
Proposed HSE Decision Issued to Applicant
Applicant Representations Received
HSE Decision Issued to Applicant
Application On Hold at the Request of Applicant
Application Withdrawn at the Request of Applicant
Application on Hold as Agreed by HSE and Applicant
HSE Approval Letter Issued to Applicant
Full Health Technology Assessment Submitted to NCPE
Delete Application
×
Are you sure you want to delete this Application?
Once it's deleted it cannot be retrieved.
Remove Status and Date
×
Are you sure you want to delete this?